跳转至内容
Merck
CN
所有图片(2)

文件

安全信息

HCD8MAG-15K

Millipore

MILLIPLEX® 人CD8+ T细胞磁珠板 - 免疫学多重检测

Simultaneously analyze multiple cytokine and chemokine biomarkers with Bead-Based Multiplex Assays using the Luminex technology, in human serum, plasma and cell culture samples.

别名:

Human CD8 T cell cytokine panel, Human cytokine multiplex kit, Luminex® human cytokine immunoassay, Millipore human cytokine panel

登录查看公司和协议定价
所有图片(2)

About This Item

UNSPSC代码:
12161503
eCl@ss:
32161000
NACRES:
NA.84

质量水平

200

种属反应性

human

制造商/商品名称

Milliplex®

assay range

standard curve range: 0.4-1,500 pg/mL
(IL-6)
standard curve range: 0.5-2,000 pg/mL
(TNFα)
standard curve range: 1-3,500 pg/mL
(MIP-1α)
standard curve range: 1-5,000 pg/mL
(Granzyme B)
standard curve range: 1-5,000 pg/mL
(IFNγ)
standard curve range: 1-5,000 pg/mL
(IL-5)
standard curve range: 10-50,000 pg/mL
(Perforin)
standard curve range: 10-50,000 pg/mL
(sFasL)
standard curve range: 2-10,000 pg/mL
(IL-4)
standard curve range: 2-10,000 pg/mL
(sCD137)
standard curve range: 2-7,500 pg/mL
(IL-13)
standard curve range: 2-7,500 pg/mL
(IL-2)
standard curve range: 20-100,000 pg/mL
(Granzyme A)
standard curve range: 4-15,000 pg/mL
(GM-CSF)
standard curve range: 400-1,650,000 pg/mL
(sFas)
standard curve range: 5-20,000 pg/mL
(IL-10)
standard curve range: 7-30,000 pg/mL
(MIP-1β)

技术

multiplexing: suitable

检测方法

fluorometric (Luminex xMAP)

运输

wet ice

相关类别

一般描述

CD8+T细胞（也称为细胞毒性T细胞，溶细胞性T细胞和杀伤性T细胞）属于能够诱导感染的体细胞或肿瘤细胞的死亡的T细胞亚群。与主要组织相容性复合体（MHC）自身抗原弱结合的T细胞被阳性选择为胸腺中的单阳性CD4+或CD8+T细胞。那些在活化后存活并成熟的CD8+T细胞成为细胞毒性细胞，表达能够识别与I类MHC分子和糖蛋白CD8结合的特异性抗原肽的T细胞受体（TCR）。CD8蛋白和MHC分子之间的亲和力有助于在抗原特异性激活过程中保持细胞毒性T细胞和靶标紧密结合。一旦被激活，CD8+T细胞通常被分类为在免疫系统内具有预定的细胞毒性作用，并经历IL-2诱导的克隆扩增，这增加了对靶抗原特异的细胞数量。然后，CD8+T细胞遍布全身，以寻找抗原阳性的体细胞/肿瘤细胞。

Luminex® xMAP®平台使用磁珠免疫分析格式，以实现理想的速度和灵敏度，同时定量多种分析物，从而显著提高生产力，同时节省宝贵的样本量。

面板类型：细胞因子/趋化因子

特异性

抗体与该面板中任何其他分析物之间的交叉反应性都为无法检测或可忽略。

应用

  • 分析物：GM-CSF，sCD137，IFNγ，sFas，sFasL，颗粒酶A，颗粒酶B，IL-2，IL-4，IL-5，IL-6，IL-10，IL-13，MIP-1α，MIP-1β，TNF-α，穿孔素
  • 推荐的样品类型：血清，血浆或组织/细胞裂解液和培养上清液
  • 推荐的样品稀释度：未稀释
  • 分析运行时间：过夜
  • 研究类别炎症 & 免疫学

特点和优势

通过在此面板中选择可用的分析物来设计多重试剂盒。

储存及稳定性

试剂盒组分建议的存储温度为2-8°C。

其他说明

灵敏度：有关单个生物标记物的灵敏度，请参阅试剂盒方案。

法律信息

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

免责声明

除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。

警示用语：

Danger

危险分类

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

靶器官

Respiratory Tract

储存分类代码

10 - Combustible liquids

WGK

WGK 3

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Chaoxu Zhang et al.
Frontiers in oncology, 10, 760-760 (2020-06-13)
Anti-PD-1 therapy has been approved for cancer treatment. However, the response rate is unsatisfactory. The expression of PD-L1 in tumor tissues is unreliable to predict the treatment response. Recent studies have suggested that exosomal PD-L1 not only exerts immunosuppressive effects
Arturo Panduro et al.
Clinical liver disease, 19(2), 41-48 (2022-03-22)
Content available: Author Interview and Audio Recording.
Antti Hurme et al.
Frontiers in immunology, 13, 869990-869990 (2022-05-10)
The emergence of novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made it more difficult to prevent the virus from spreading despite available vaccines. Reports of breakthrough infections and decreased capacity of antibodies to neutralize variants
Wiebke Naujoks et al.
Frontiers in immunology, 11, 573200-573200 (2020-10-27)
Obesity is associated with an increased risk for several cancer types and an altered phenotype and functionality of natural killer (NK) cells. This study aimed to investigate the association of overweight and obesity with NK cell functions and receptor expression
Emelie Foord et al.
Journal of immunology research, 2020, 7375947-7375947 (2020-08-25)
PD-1/PD-L1 blockade has revolutionized the field of immunooncology. Despite the relative success, the response rate to anti-PD-1 therapy requires further improvements. Our aim was to explore the enhancement of T-cell function by using novel PD-1-blocking proteins and compare with clinically
查看所有相关文献

相关内容

Multiplexing Inflammation Signaling Pathways | MILLIPLEX® Assays

See how multiplexing the inflammation signaling pathway with MILLIPLEX® inflammation assays or cell signaling assays can help researchers bridge the gap between immunology and cell signaling, including investigating T cell signaling, Th Cell differentiation, inflammatory response signaling, and sepsis signaling.

Immunology Multiplex Assays | MILLIPLEX®

Immunology multiplex assays like MILLIPLEX® allow simultaneous investigation of immune biomarkers, saving time and resources in research.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门